Overview

SAM-e for the Treatment of Depression in Patients With Parkinson's Disease

Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
This study will test a chemical called s-adenosyl-methionine (SAM-e) for the treatment of depression in patients with Parkinson's disease (PD).
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
New York University School of Medicine
NYU Langone Health
Collaborators:
National Center for Complementary and Integrative Health (NCCIH)
Office of Dietary Supplements (ODS)
Treatments:
Citalopram
Dexetimide